Tempus logo

Tempus

North America, Illinois, United States, Chicago

Description

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

Investor Profile

Tempus has made 4 investments, with 1 in the past 12 months and 50% as lead.

Stage Focus

  • Series Unknown (50%)
  • Series A (25%)
  • Post Ipo Equity (25%)

Country Focus

  • United States (75%)
  • United Kingdom (25%)

Industry Focus

  • Biotechnology
  • Genetics
  • Life Science
  • Therapeutics
  • Health Care
  • Neuroscience
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Tempus frequently co-invest with?

Co-Investments: 1
AbbVie Biotech Ventures
North America, Illinois, United States, North Chicago
Co-Investments: 1
KS
North America, New York, United States, New York
Co-Investments: 1

Which angels does Tempus often collaborate with?

PG
North America, Illinois, United States, Chicago
Shared Deals: 1
David R. Walt
North America, Massachusetts, United States, Boston
Shared Deals: 1
Shared Deals: 1
BG
North America, Washington, United States, Seattle
Shared Deals: 1
Shared Deals: 1
MT
North America, New York, United States, New York
Shared Deals: 1
EL
North America, Illinois, United States, Chicago
Shared Deals: 1

What are some of recent deals done by Tempus?

Personalis

Menlo Park, California, United States

Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.

BiotechnologyGeneticsHealth CareHealth Diagnostics
Post Ipo EquityAug 16, 2024
Amount Raised: $36,145,000
Akrivia Health

Oxford, Oxfordshire, United Kingdom

Real-world data and evidence, clinical trial optimisation and molecular characterisation for mental health and dementias

BiotechnologyHealth CareNeuroscience
Series AJun 20, 2021
Amount Raised: $5,941,065
Exicure

Chicago, Illinois, United States

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

BiotechnologyGeneticsLife ScienceTherapeutics
Series UnknownSep 27, 2017
Amount Raised: $20,000,000
Exicure

Chicago, Illinois, United States

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

BiotechnologyGeneticsLife ScienceTherapeutics
Series UnknownOct 21, 2015
Amount Raised: $14,798,400